Healthcare Professionals – e-Learning

Learning Objectives:

• Recall updates to National Advisory Committee on Immunization (NACI) recommendations for influenza vaccination and expected changes to vaccine composition
• Describe the role of real-world evidence in clinical decision making
• Explain the association between influenza infection and cardiovascular events, loss of functional independence, and frailty in older adults
• Counsel older adults on the impact of vaccination on reducing the above risks and vaccine options indicated for this population

This continuing education is free for members of CanadianHealthcareNetwork.ca. Visit www.canadianhealthcarenetwork.ca to sign up.

Visit eCortex.ca to register.

Learning Objectives:

At the end of this on-demand webinar, you will be able to:

• Describe the burden of RSV disease in the adult population and risk as related to age and underlying medical conditions Identify risk factors for severe complications of RSV and why older adults face a higher risk
• Understand new clinical evidence supporting RSV vaccination and current vaccine technologies to address age-related decline in immunity
• Apply best practices and tools for identifying adults at risk of serious outcomes from RSV in your practice
• Acquire strategies for implementing RSV vaccination into practice to optimize adult immunization

This continuing education is free for members of CanadianHealthcareNetwork.ca. Visit www.canadianhealthcarenetwork.ca to sign up.

Visit eCortex.ca to register.

Learning Objectives:

At the end of this on-demand webinar, you will be able to:

• Recall updates to NACI recommendations for influenza vaccination and expected changes to vaccine composition.
• Describe the role of real-world evidence in evaluating the effectiveness of influenza vaccination in specific populations.
• Explain the association between influenza infection and cardiovascular events, loss of functional independence, and frailty in older adults.
• Describe implementation strategies to support older adult patients in the pharmacy during the busy influenza season.

Supported by educational funding from CSL Seqirus.

Visit eCortex.ca to register.

Learning Objectives:

At the end of this on-demand webinar, you will be able to:

• Understand the burden of influenza and its consequences on the older adult population (65+ years)
• Discuss recommendations for seasonal influenza under the NACI statement for the 2024-2025 season
• Describe different influenza vaccine recommendations based on evidence-based recommendations
• Discuss best practices for influenza vaccination delivery based on age group and health outcomes using clinical/case studies

This program is an unaccredited learning activity supported by educational funding from Sanofi.

Visit eCortex.ca to register.

This training module is intended as a refresher on how to administer the flu vaccine. The module can be completed within 30 minutes.

The iMD Patient Engagement Platform is a web-based patient education platform that is available on any device with internet. iMD Health enables healthcare providers to bring their patient sessions to life through the seamless integration of professionally-vetted diagrams, educational resources, brochures and videos covering over 1,800 medical conditions, procedures and treatment options.

To get your account, visit app.imdhealth.com/signup.

This is a 30-minute CFPC Mainpro+ certified eCME program for Canadian HCPs. The goal is to provide education on the burden of influenza in older adults, and the clinical data used to support vaccination options for this high-risk population. This program is designed to provide practical information on available influenza vaccines in Canada, concurrent administration with other vaccines and national recommendations in order to support clinicians with discussions on optimal protection for older adults.

Learning Objectives

Upon completion of this continuing education program participants will be better able to:

• Describe the burden of influenza in older adults and the importance of influenza vaccination
• Evaluate the evidence pertaining to influenza vaccines in older adults
• Apply NACI 2024-2025 recommendations for influenza vaccination and concurrent administration with other vaccines in older adults

Visit mdBriefCase to register.

This is a 30-minute CCCEP certified eCME program for Canadian pharmacists. The goal is to provide education on the burden of influenza, and influenza prevention and control measures, with a focus on older adults, and the clinical data used to support vaccination options for this high-risk population. This program is designed to provide practical information on the available influenza vaccines in Canada, and national recommendations in order to support discussions with older adults on the optimal protection available to them.

Learning Objectives

Upon completion of this continuing education program participants will be better able to:

• Describe the burden of influenza in older adults and the importance of influenza vaccination
• Apply NACI 2024-2025 recommendations for influenza vaccination and concurrent administration with other vaccines in older adults
• Implement influenza vaccination in clinical practice

Visit mdBriefCase to register.

This is a 15-minute expert brief for Canadian primary care providers and other healthcare professionals. Due to the limited therapeutic options available to manage RSV disease, the goal is to provide education on disease prevention. This expert brief is designed to provide practical information on passive immunization options available for infants in Canada, with a focus on NACI’s recommendations for the use of nirsevimab, the recently authorized long-acting monoclonal antibody. The expert brief video will feature a conversation between a Pediatric Infectious Disease Specialist and a Family Physician.

Learning objectives:
After viewing this expert brief, participants will be better able to:

• Recognize the burden of RSV disease in all infants
• Summarize NACI guidance for a universal RSV immunization program
• Implement RSV immunoprophylaxis in clinical practice

Visit mdBriefCase to register.

This 60-minute webinar is designed to provide Canadian HCPs with practical information on passive immunization options available in Canada, with a focus on the newly authorized long-acting monoclonal antibody nirsevimab, and the maternal RSVpref vaccine. The webinar will discuss RSV prevention through case studies, and highlight how a hospital order set can support implementation of the new RSV immunoprophylaxis in clinical practice.

Learning objectives:
Upon completion of this program, participants will be able to:

• Describe the prevalence and burden of RSV disease in all infants
• Summarize NACI guidance and supporting evidence on passive immunization for RSV
• Implement a hospital order set for RSV prevention to support clinical practice

Visit mdBriefCase to register.

This is a 60-minute eCME for Canadian HCPs. Due to the significant burden of disease of RSV in infants and young children, the goal is to provide education on the role of RSV immunoprophylaxis in disease prevention. This program is designed to provide practical information on recently authorized RSV immunoprophylaxis available in Canada, with a focus on nirsevimab, a long-acting monoclonal antibody. Utilizing case studies and expert videos, the program will review the burden of RSV disease in infants, supporting evidence for recently approved RSV immunoprophylaxis, NACI guidance for RSV immunoprophylaxis for all infants and considerations for the use of nirsevimab in clinical practice.

Learning objectives:
Upon completion of this continuing education program participants will be better able to:

• Cite the prevalence and burden of RSV disease in infants
• Evaluate clinical and safety data of recently approved RSV immunoprophylaxis for infants
• Summarize NACI guidance on RSV immunoprophylaxis for all infants
• Implement RSV immunoprophylaxis for infants in clinical practice

Visit mdBriefCase to register.

Target Audience and Goal Statement

The intended audience for this activity is obstetricians/gynecologists, nurse practitioners, and other healthcare professionals involved in the management of expectant parents.

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants in the United States. Infants and certain young children are at higher risk for severe illness, especially in the setting of premature birth, immune compromise, or comorbid conditions. Recently, new preventive options have become available, including a maternal RSV vaccine for expectant mothers and a long-acting immunoprophylactic agent for infants and certain young children. Education is needed to keep clinicians up to date on the latest evidence-based recommendations for RSV prevention. This CME activity provides education on the burden of RSV disease in infants and evaluates passive immunization approaches. Experts in obstetrics, maternal-fetal medicine, and pediatric infectious disease will discuss effective comprehensive, interprofessional strategies to help prevent RSV transmission and severe illness among newborns.

Upon completion of this activity, participants will:

• Review the significant patient, parent, and healthcare burden associated with infant and young child RSV infections and alterations in RSV season trends.
• Characterize approved monoclonal antibodies for RSV prevention in infants and young children by pharmacology, dosing, administration, and recent safety and efficacy data.
• Discuss interprofessional strategies to prevent and mitigate RSV infections in infants and young children, including evidence-based recommendations.

Visit Medscape to register.

Target Audience and Goal Statement

This activity is intended for obstetricians/gynecologists, primary care physicians, nurse practitioners, and nurses.

The goal of this activity is for learners to be better able to apply lessons learned from implementing novel maternal vaccines to prepare for emerging vaccines for congenital cytomegalovirus.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the
• Importance of vaccination timing prior to pregnancy
• Challenges associated with vaccination prior to pregnancy
• Emerging vaccines to protect fetal health
• Have increased confidence in
• Effectively addressing vaccine-related misinformation and concerns among patients who are pregnant or planning on becoming pregnant

Visit Medscape to register.

This is a 45-minute, CFPC/CCCEP/OPQ-accredited eCME program for primary care physicians, pharmacists and other travel health practitioners. The goal is to equip healthcare providers with knowledge about the mosquito-borne chikungunya virus, including transmission, risk factors, diagnostic criteria and disease management, while also unveiling new preventative strategies, including vaccines in development, to protect against the chikungunya virus.

Learning objectives:
Upon completion of this continuing education program, participants will be better able to:

• Explain the epidemiology and burden of chikungunya virus
• Describe the clinical presentation and morbidity of chikungunya virus infection
• Counsel travellers on preventative strategies to reduce mosquito-borne viral infections
• Describe the chikungunya vaccines under development and the potential role of vaccination in preventing chikungunya virus infection

Visit mdBriefCase to register.

Chikungunya virus (CHIKV), a mosquito-borne alphavirus, is the causative agent of chikungunya (CHIK) disease, a condition with low mortality but high acute and chronic morbidity resulting in high overall burden of disease. Infection rates of CHIKV have increased in recent years, and this upward trend is expected to continue as vector habitats continue to expand. This program will provide participants with key insights into CHIKV, including its epidemiology, clinical manifestations, diagnosis, current management and preventative strategies, including vaccines in development. The objective is to enable participants to enhance their knowledge of the disease and diagnostic skills, implement effective management strategies and contribute to public health efforts to protect against the virus.

This program has received an educational grant or in-kind support from Valneva.

Learning objectives:
Upon completion of this continuing education program, participants will be better able to:

• Explain the epidemiology and burden of chikungunya virus
• Describe the clinical presentation and morbidity of chikungunya virus infection
• Counsel travellers on preventative strategies to reduce mosquito-borne viral infections
• Describe he chikungunya vaccines under development and the potential role of vaccination in preventing chikungunya virus infection

Visit mdBriefCase to register.

Target Audience and Goal Statement

This educational activity is intended for an audience of primary care physicians, infectious disease specialists, and public health and preventative medicine specialists.

The goal of this activity is for learners to be better able to identify individuals at risk and how to communicate with potential recipients about the risk/benefit of chikungunya virus vaccines.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • Latest data on the burden of chikungunya disease
  • Data on chikungunya virus vaccines
• Have greater competence related to
  • Identifying who would benefit from the chikungunya vaccine

Visit Medscape to register.

Target Audience and Goal Statement

This educational activity is intended for a global audience of primary care physicians, infectious disease specialists, public health and preventative medicine specialists, nurses, and pharmacists.

The goal of this activity is for learners to be better able to identify patients who are at risk for JEV infection, and be aware of the different Japanese encephalitis vaccines.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • Characteristics of JEV acquisition (eg, by < 1 month duration)
  • JEV vaccines
• Have greater competence in
  • Identifying travelers who are at risk of JEV

Visit Medscape to register.

Learning Objectives:

• Describe the impact of climate change on the risk of insect-borne diseases during travel.
• Explain the epidemiology, clinical presentation, outcomes and risks of common mosquito-borne diseases.
• Determine the non-pharmacological recommendations for the protection against mosquito-borne diseases.
• Discuss the different vaccine options to protect against different mosquito-borne diseases related to travel.

Supported by educational funding from Valneva.

Visit eCortex.ca to register.

A rising number of Canadians are diagnosed with Lyme disease each year. This program aims to help clinicians effectively identify and treat Lyme disease in their patients. The program will review the clinical presentation and treatment of Lyme disease, with the overall goal of supporting clinicians in optimizingearly recognition and treatment of this condition.

Learning objectives:

Upon completion of this continuing education program, participants will be better able to:

• Describe the clinical presentation of Lyme disease
• Discuss appropriate treatment options for Lyme disease
• Advise patients on preventative measures for Lyme disease

Visit mdBriefCase to register.

Target Audience and Goal Statement

This activity is intended for a Canadian audience of primary care physicians, obstetricians/gynecologists, oncologists, dentists, otolaryngologists, public and preventive health specialists, nurses, and pharmacists.

The goal of this activity is for learners to be better able to understand the challenges in human papillomavirus (HPV) vaccine uptake and key practical steps and communication triggers that are needed for successful HPV vaccine recommendation or administration.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the Identification of expert recommended practical approaches to increase HPV vaccine uptake such as use of technology and patient engagement (eg, discussing link between virus and cancers)
• Demonstrate greater confidence in their ability to Effectively implement in daily practice communication to unvaccinated people regarding the benefits of HPV vaccination

Visit Medscape to register.

The world has been living with COVID-19 for over 4 years. With the introduction of COVID-19 vaccines, it has been estimated that millions of cases, hospitalizations and deaths have been avoided globally. As the virus has continued to evolve, additional vaccine doses and updated vaccine formulations have been introduced to continue to provide protection from this virus. Canadians had one of the highest COVID-19 vaccine uptake in the world, with more than 4 out of 5 of the total population receiving at least 1 dose of a COVID-19 vaccine. With each subsequent dose, the uptake has been much lower, with only 16.3% of the total population receiving the last vaccine (XBB.1.5 formulation).

Pharmacists have been instrumental in vaccinating large portions of the community and providing information throughout the pandemic. With a new vaccine formulation being introduced in the fall, pharmacists will be relied upon to protect their patients and encourage vaccine uptake. This program is designed to provide pharmacists with a quick COVID-19 update, to allow them to provide them most current information for their patients.

Learning objectives:

Upon completion of this continuing education program, participants will be better able to:

• Summarize the current state of the COVID-19 pandemic and the role of pharmacists in vaccination
• Evaluate the effectiveness of the COVID-19 vaccine in preventing symptomatic disease and hospitalizations
• Explain the importance of coadministration of adult vaccines such as COVID-19 and influenza
• Formulate strategies to improve vaccine uptake in pharmacy patients

This program has received an educational grant or in-kind support from Moderna Biopharm Canada Inc.

Visit mdBriefCase to register.